濮阳东方医院男科收费比较低(濮阳东方医院男科价格低) (今日更新中)

BEIJING, Sep. 1 (Xinhuanet) -- Apple lost another iPhone prototype at a Bay Area bar, according to media reports Thursday.It is reported that an Apple employee lost a prototype iPhone at San Francisco bar Cava 22 in late July, which is a tequila bar in the mission district.A joint investigation by Apple and San Francisco police searched a local house but could not find it, the reports added.It seems that Apple employees learned nothing from last year’s lost iPhone scandal. A prototype iPhone 4 was lost in a Redwood City bar last year.Apple has denied any knowledge of the incident, and San Francisco police stated that Apple did not file a police report for the lost merchandise.If the reports are true, it would be a big blow to Apple’s ego since the company takes pride in its secretive nature.

LOS ANGELES, June 5 (Xinhua) -- A latest study has found no evidence that screening for ovarian cancer may reduce the risk of dying from the disease, it was reported on Sunday.Screening, however, does increase the likelihood of unnecessary invasive procedures, according to researchers at the University of Utah.The researchers presented their findings at an on-going meeting of the American Society of Clinical Oncology in Chicago, The Los Angeles Times said.Researchers studied 78,216 women, ages 55 to 74, who participated in the National Cancer Institute's Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Half of the women received the usual care from their OB-gyns, and half received a CA 125 screening every year for six years and an ultrasound every year for four years. They were then followed for a maximum of 12 years.The researchers observed 212 ovarian cancers in the screened group and 176 in the normal care group. There were 118 ovarian cancer deaths in the screened group and 100 in the normal care group. The differences were not statistically significant. Overall, there were 2,924 deaths from all causes in the screened group and 2,914 in the normal care group.But the researchers also observed that 3,285 women had false- positive diagnoses from the screening. Among those, 1,080 underwent surgery that included an oophorectomy (surgical removal of one or both ovaries). Fifteen percent of those who had surgery developed major complications as a result. Overall, 1,771 women in the screened group (7.7 percent) had an oophorectomy, compared with 1,304 in the normal care group (5.8 percent)."We conclude that annual screening for ovarian cancer ... does not reduce disease-specific mortality in women at average risk for ovarian cancer but does increase invasive medical procedures and associated harms," the researchers said in the study.New data presented at the meeting also showed that the widely used cancer drug Avastin can improve treatment of ovarian cancer, The Times said.About 21,880 American women are diagnosed with ovarian cancer each year and about 13,850 die from it, according to the American Cancer Society. Because it produces few symptoms, the disease is typically not diagnosed until it has become advanced and spread throughout the body. As a result, five-year survival is only about 30 percent, and the disease is one of the five most deadly cancers among women. Being able to detect the cancer at an earlier stage when it might be more curable could thus, theoretically, improve the survival rate.The tests most commonly used to detect ovarian cancer include a transvaginal ultrasound to look for tumor masses and a blood test that screens for increased levels of a tumor marker called CA 125.

TOKYO, Sept. 23 (Xinhua) -- Japan's H-2A rocket carrying a new information gathering satellite was launched at the Tanegashima Space Center in Kagoshima Prefecture on Friday, local media reported.Japan has already introduced three information-gathering satellites in the wake of a missile launch by Democratic People's Republic of Korea, and the latest one will replace the No. 2 satellite which has passed its use-by date, Kydo News said.Japan's H-2A rocket lifts off from the launchiung pad at the Tanegashima space centre in Kagoshima prefecture, Japan's southern island of Kyushu on September 23, 2011. Japan launched a new spy satellite into orbit September 23, officials saidThe development cost of the fourth satellite has reached 35.9 billion yen and its launch expenses have come to 10.4 billion yen, according to the government.The Japan Aerospace Exploration Agency and Mitsubishi Heavy Industries Ltd. were forced to put off the launch three times during the past four weeks due to the approach of a powerful typhoon and discovery of a system glitch. The rocket was initially scheduled to be sent into orbit on Aug. 28.

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

STOCKHOLM, July 7 (Xinhua) -- A patient has been given a new trachea made from a synthetic scaffold seeded with his own stem cells in a Stockholm's hospital, the Swedish medical university Karolinska Institutet said on Thursday.The operation was performed on June 9th at Karolinska University Hospital in Huddinge and the patient, a 36-year old man, has been well on the way to recovery and would be discharged from the hospital on Friday, the university said in a statement.The patient had been suffering from late stage tracheal cancer with the tumor had reached approximately 6cm in length and was extending to the main bronchus.Since no suitable donor windpipe was available, the transplantation of the synthetic tissue engineered trachea was performed as the last possible option for the patient.The successful transplantation of tissue engineered synthetic organs, referred to as regenerative medicine, could open promising therapeutic possibilities for the thousands of patients who suffer from similar conditions.Transplantations of tissue engineered windpipes with synthetic scaffolds in combination with the patient's own stem cells as a standard procedure means that patients would not have to wait for a suitable donor organ.This would be a substantial benefit for patients since they could benefit from earlier surgery and have a greater chance of cure, according to the statement.

来源：资阳报